INTRODUCTION
Liver cirrhosis (~80% of cases) is the most common cause of ascites. Ascites is the pathological accumulation of fluid in the peritoneal cavity. Malignant conditions, including peritoneal carcinomatosis, and benign conditions, including tuberculous peritonitis, heart failure, pancreatic disease, and renal disease, also contribute to the development and accumulation of ascites. Malignant ascites account for approximately 10% of all cases of ascites. 1 Ascites fluid analysis by paracentesis can provide useful information for determining the cause of ascites. 2, 3 Several potential parameters for the diagnosis of malignant ascites have been evaluated to date, including protein levels in ascites, ascites/serum concentration ratio of protein (protein A/S), lactate dehydrogenase (LDH) levels in ascites, ascites/serum concentration ratio of LDH (LDH A/S), 4 carbohydrate antigen 19-9 in ascites, 5 serum-ascites albumin gradient, 6 fibronectin in ascites, and cholesterol in ascites. 7 However, until now, no parameter was able to completely differentiate the cause of malignant ascites; currently, the gold standard for diagnosing malignant ascites is the presence of tumor cells in ascites. 8 The specificity of this method is very high, but it has low sensitivity (40-60%) due to the lack of cell exfoliation, which is common to all malignancies. 5 This low sensitivity sometimes leads to invasive procedures, including laparoscopy, to acquire peritoneal tissues. hydronephrosis. 14 The benign group was defined as patients who had no evidence of malignancy by clinical and radiological findings.
Collection and assessment of ascites
All patients underwent paracentesis to evaluate aCEA. The collected ascites were analyzed for cytology and tumor markers. For cytologic examination, the collected peritoneal fluid was centrifuged and smeared on the slides and fixed with cytospray; Papanicolaou and Giemsa staining were performed. The levels of aCEA and serum CEA (sCEA) were measured using electrochemiluminescent immunoassay on a Cobas e-601 analyzer (Roche Diagnostics, Mannheim, Germany).
Statistical analyses
All statistical analyses were performed using SPSS 20.0 (IBM Co., Armonk, NY, USA). The optimal cut-off value was determined using receiver operating characteristic (ROC) curve analysis. Sensitivity was calculated as true positives/(true positives+false negatives), and specificity was calculated as true negatives/(true negatives+false positives). Positive predictive value (PPV) and negative predictive value (NPV) determinations were made from the established cut-off values,
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Tumor marker assays
The median level of aCEA among all patients was 0.82 ng/mL (range 0.2-16,518 ng/mL). The median levels of aCEA in the CRC and benign groups were 778.85 ng/mL (range 0.97-16,518 ng/mL) and 0.5 ng/mL (range 0.2-3.45 ng/mL), respectively. The difference between the two groups was statistically significant (p<0.001), as shown in Fig. 1 .
According to ROC curve analysis, the optimal cut-off value of aCEA to predict the occurrence of peritoneal carcinomatosis was 3.89 ng/mL. The sensitivity and specificity were 96.3% and 100%, respectively (PPV, 100%; NPV, 98.3%).
Moreover, the area under the curve for aCEA was 0.996 (p<0.001). By comparison, the optimal cut-off value for sCEA for predicting the occurrence of peritoneal carcinomatosis was 8.64 ng/mL. The sensitivity and specificity were 84.2%
and 91.3%, respectively (PPV, 81.0%; NPV, 92.9%); the AUC for sCEA was 0.914 (p<0.001). These results are summarized in Table 2 and Fig. 2 . The mean level of aCEA in the CRC group with negative cytology was higher than that in the CRC group with positive cytology; but this difference was not statistically significant (2075.5 ng/mL vs. 1093.6 ng/mL, p=0.06).
Univariate and multivariate analyses using logistic regression were performed to evaluate the factors predicting the occurrence of peritoneal carcinomatosis. In univariate analysis, age, aCEA, sCEA, carbohydrate antigen 19-9 in ascites, carbohydrate antigen 19-9 in serum, serum-ascites albumin gradient, protein A/S, and LDH A/S were significant predictors for the occurrence of peritoneal carcinomatosis.
However, in the multivariate analysis, aCEA was the only significant predictor for the occurrence of peritoneal carcinomatosis (odds ratio 4.900, 95% confidence interval 1.878-12.783, p=0.001) ( Table 3) .
DISCUSSION
This study showed that sensitivity, specificity, PPV, and NPV of aCEA were high, and aCEA was a significant factor for predicting the occurrence of peritoneal carcinomatosis. Our results suggest that aCEA may be a useful parameter for the diagnosis of CRC with peritoneal carcinomatosis, and that aCEA of 3.89 ng/mL could be considered as a cut-off value.
CRC is the third most common cancer in Korea. Peritoneal
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The Korean Journal of Gastroenterology carcinomatosis is the second most frequent metastatic pattern in advanced CRC. 15 Peritoneal fluid cytology is the gold standard to confirm peritoneal carcinomatosis due to its high specificity. However, the low positive detection rate is its limitation in clinical practice. In advanced ovarian cancer with peritoneal dissemination, the detection rate of malignant cells in ascites has been reported to be as high as 89%, 16 and in advanced gastric cancer with peritoneal dissemination, the detection rate has ranged from 42.3-59%. 17, 18 However, in advanced CRC with peritoneal dissemination, the detection rate of malignant cells in ascites, using peritoneal cytology assays, has been as low as 5. 24 used an empiric cut-off value, and Loewenstein and Zamcheck 9 reported a cut-off value for aCEA in malignant ascites of 10 ng/mL (the highest aCEA level of the benign group). Recently, Kaleta et al. 5 reported that the optimal cut-off value of aCEA to differentiate the causes was >3.5 ng/mL when the cut-off value was selected to achieve a specificity of 95.2% by ROC curve analysis.
In previous studies, the sensitivity and specificity of aCEA in patients with advanced CRC ranged from 31.5-48.3% and from 95.2-100%, respectively. 5, 9 In our study, we assessed aCEA in patients with advanced CRC and determined an optimal cut-off value using a ROC curve. We identified an optimal cut-off value of 3.89 ng/mL for aCEA, and the sensitivity and specificity were 96.3% and 100%, respectively.
Our study showed that only 21.1% of patients had positive cytology, even though all patients had clinical peritoneal carcinomatosis. The mean aCEA value of the CRC group was higher in patients with negative cytology than in those with positive cytology. 25, 26 Hence, these results show a low level of positive cytology in patients with aCEA. There are several possible mechanisms for this. First, this might be due to the low peritoneal metastatic potential of CRC cells. 27 Second, delayed examination could yield false-negative results due to lysis of tumor cells. 28 Third, peritoneal inflammation could make the difference between malignant cells and atypical or reactive mesothelial cells that are ambiguous in body fluids. 21 We hypothesized that the level of aCEA would positively correlate with the level of sCEA and investigated the relationship between them. However, our results did not show any correlation between aCEA and sCEA. There are several limitations in this study. First, our study did not include patients who had other malignant ascites, such as gastric or ovarian cancer with ascites. Therefore, our study does not provide realistic and clinically available data. Second, there was no CRC patient who had ascites but did not had peritoneal carcinomatosis in this study. Therefore, whether there was an elevation of aCEA in CRC patients without peritoneal carinomatosis remains unclear.
In conclusion, our study demonstrated that aCEA may have predictive value for the occurrence of peritoneal carcinomatosis, and this finding suggests that aCEA may be helpful in the initial diagnosis of peritoneal carcinomatosis. According to the results of this study, aCEA may be a useful parameter for diagnosing peritoneal carcinomatosis in advanced CRC patients, with a suggested cutoff value of 3.89 ng/mL.
Further study that includes patients with other malignant ascites may be necessary to validate these findings.
